Regulatory process for biological paper

timer Asked: Feb 24th, 2019
account_balance_wallet $20

Question Description

I need 5-pages paper about regulatory process for biological, I have attached the general question and how to write the paper, but the specific Scenario is this:

You are a scientist working for health Canada. you review dossiers in the Biology & Gene Therapies Directorate. A dossier is being submitted for a DNA plasmid expressing the melanoma antigen recognized by T-Cells (MART-1) gene from rats. This plasmid is proposed to be used to treat malignant melanoma in humans, by inducing cross-reactive immune responses to the human MART gene product, thus breaking immunological tolerance for self antigens. This concept has been proven in dogs by a licensed veterinary product in Australia. That DNA plasmid product express the human MART gene, and cure dogs of melanomas.

I have attached some important questions have to be answered in the paper. there is an example attached( please follow it) Lastly, the reference should be the same as in the example.

Regulatory process for biological paper
Regulatory process for biological paper
Example Assignment Paper Rebecca Sheets BIOL 583 2018 Introduction/Scenario: I am a representative of an applicant; my organization is part of a complex public-private partnership to develop a global HIV/AIDS vaccine. Funding has been granted by our organization to an HIV/AIDS vaccine researcher in China who has developed a DNA plasmid prime-viral vector boost system. He has taken this to Phase 2 in trials in China using vaccines manufactured in China. He is working with a clinical trials network that has sites throughout the U.S. and in some other countries. This network is also funded by my organization. Results of a clinical trial performed by another network demonstrated modest efficacy of a viral-vector prime-protein boost. [1,2] Because of those results, the clinical trials network we fund and with which the Chinese researcher is working wants to add a protein boost to his regimen. The challenge is that the protein is being manufactured in the U.S., so the applicant will be the U.S. partner: my organization. We will seek authorization to import the protein into China so that the Chinese researcher may conduct a Phase 1 clinical trial of this 3-component candidate vaccine regimen. The protein will also be studied in clinical trials in the U.S. alone or as a component in other candidate regimens. An initial Phase 1 firstin-human trial of the protein alone will be conducted in the U.S. and a pre-IND meeting with the U.S. FDA was held to guide that. This paper focuses on the process in China to gain authorization to conduct a Phase 1 clinical trial there using the Chinese researcher’s prime-boost regimen with the US protein. This would be the initial first-in-human trial of this complete combination of 3 components combined in a single regimen, although there will be clinical experience with each component separately and 2 of the 3 components combined. Possibility for a meeting between the Chinese regulators and the applicant Based on publicly available information in English, e.g., the Chinese 1 Food and Drug Administration’s (CFDA) website, it is not clear whether there is a possibility for a meeting between the Chinese regulators and our partnership (funding organization and applicant, clinical trials network, Chinese researcher). [3] However, we were able to obtain a meeting with the CFDA prior to filing a submission to request authorization to conduct clinical trials in China with a vaccine candidate produced in the U.S. to be imported to the Chinese clinical trial site. We refer to this as a pre-IND meeting, although it isn’t technically called that in China. We were not able to obtain a similar meeting with the Chinese national control lab, the National Institute for Food and Drug Control (NIFDC). Nonetheless, the CFDA did convey expectations that the NIFDC would expect to receive specimens for testing and lot release control prior to CFDA authorizing the clinical trial. [see 4 for requirements for authorization] 1 Known in China as the State FDA or SFDA 1 Type of Dossier We will be submitting a request for clinical trial approval following the Application and Approval Procedure for Clinical Trials. [5] The Chinese refer to this as Drug Registration: Biologics Register: Preventive biological products. The requirements come from Board Order No. 17 for Drug Registration. [personal communication from Shao Y] Outline of Dossier The Chinese requirements, specified in Board Order No. 17 [personal communication from Shao Y] are for submission of document as follows: 1. Summary of documents. (1) Name of the new product; (2) Documents of proof; (3) The purpose and basis of the topic; (4) Product description in details, drafting notes and references; (5) Packaging and label design. 2. Summarize the overall findings and evaluation data. 3. Research data on bacteria (viruses) used for production. (1) Source of bacteria (viruses), characteristics and identification information (2) Establishment and testing of seed lot (3) Bacteria (viruses) passages stability data (4) Testing results of the seed lot from National Institutes for Food and Drug Control 4. Research data on cell bank used for manufacturing. (1) Source, properties and identification of cell line (2) Establishment and testing of cell bank (3) Passage stability of cell bank (4) Testing results of the working cell bank from National Institutes for Food and Drug Control (5) Source of the culture medium, added ingredients, and quality standards. 5. Manufacturing processes. (1) Vaccine production data, the theoretical and experimental basis and testing data (2) Reagent composition and formulation and testing data, source and quality standards of excipients / adjuvants. 6. Quality control data, pre-clinical efficacy and safety data (1) Quality control data and registration standards (2) Testing methods and data (3) Comparative study data with similar products (4) Data of antigenicity, immunogenicity and protection testing in animals (5) Data on allergy testing in animals (6) Data on animal safety testing. 7. Manufacturing and draft testing procedures, with drafting instructions and the relevant literature. 2 8. Manufacturing and testing data of samples submitted for clinical trial testing (by CFDA). 9. Preliminary stability testing data. 10. Compliance certification on production, research and animal testing. 11. Clinical trial program, research programs and informed consent draft. Special Program This scenario does not have a special program. However, CFDA has verbally assured that products for HIV/AIDS would be handled in exceptional manners given the public health urgency and lack of existing preventive vaccines for this disease. Pediatric Studies The CFDA does not have (to my knowledge or in English on their website) specific requirements for pediatric studies like those required in the US by PREA or in EMA by the Pediatric Medicine directive. However, adolescents are at high risk of acquiring HIV as they become sexually active. In China, one large population of HIV-positive individuals are those that use injection drugs. Injection drug use can be initiated in childhood, as well as in adulthood. Pregnant women who are not diagnosed with HIV and thus, not afforded access to therapeutics that can prevent mother-to-child-transmission of HIV, might give birth to babies who acquire HIV before or during birth or while breast-feeding after birth. For these reasons, it would be appropriate to perform pediatric studies at some point during the development of HIV/AIDS vaccines. This matter needs to be discussed with regulators in many countries, including China, as development advances. However, given the high risk of failure to prevent HIV acquisition of HIV vaccine candidates, pediatric studies are not yet justified. In this instance, it is too early to have such discussions with CFDA, as clinical trials have yet to be initiated with the combination regimen. Guidances and Regulations Among the many guidances and regulations that are applicable, including all (or virtually all) of China’s Drug laws, the following list highlights some relevant to this case: • • • • Drug Registration (Board Order Number 17); Attachment 3: Biologics Register data classification and reporting requirements; Section 2. Preventive biological products [personal communication with Shao Y] Examination & Approval for Clinical Trials of Imported (incl. from Hong Kong, Macao, and Taiwan) preventive biological products dated 2013-12-06 [4] Special Review and Approval Procedure for Drug Registration by the State Food and Drug Administration [6] SFDA Order No. 28: Provisions for Drug Registration [7] 3 In addition, CFDA follows ICH guidelines, WHO guidelines and recommendations, and would apply their requirements/regulations for HepB vaccine to this product as this is only currently existing recombinant vaccine marketed in China that is sufficiently similar and could serve as a model for requirements, even though it would be quite an inexact model. Other relevant requirements would be those for Good Clinical Practices, Good Manufacturing Practices, and Good Laboratory Practices. Bibliography or Reference List [1] Rerks-Ngarm S, Pittisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. 2009 NEJM 361(23):2209-20. [2] Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. 2012 NEJM 366(14):1275-86. [3] Chinese Food and Drug Administration website in English: (accessed 2/1/2018) [4] CFDA document: Examination and approval for clinical trials of imported (incl. from Hong Kong, Macao, and Tiawan) preventive biological products dated 2013-12-06:; (accessed 2/1/2018) [5] CFDA: Application and Approval Procedure for Clinical Trials: (accessed 2/1/2018) [6] CFDA document: SFDA Decree No. 21 Special Review and Approval Procedure for Drug Registration of the State Food and Drug Administration: (accessed 2/1/2018) [7] CFDA document: SFDA Order No. 28: Provisions for Drug Registration: (accessed 2/1/2018) 4

Tutor Answer

School: Cornell University


I am a scientist working at Health Canada, working under the directorate of Biology and Gene Therapy.
I have been tasked with the responsibility of reviewing a dossier on the applicability of a DNA plasmid
in treating malignant melanoma in humans through cross-reactive immune responses to the human
MART gene product, and as a resulting dismantling the cycle of immunological tolerance among selfantigens. The research has been considered viable due to its recent success when conducted on dogs
through a certified veterinary commodity in Australia. This paper is therefore a review of some of the
significant considerations that have to be made before and after the submission of the research dossier.
Possibility of a meeting between the applicant and regulators.
A meeting between the national regulators and the applicant remains unknown due to the fact that the
regulator’s official website offers no such details. [1] However, a meeting between the two parties
could be easily arranged to allow for the formalization of the key concepts that are discussed in the
proposal. In addition, the meeting would provide a good opportunity for various elementary
assessments on the research to be conducted by both parties independently. The meeting would
primarily involve members from Health Canada’s department of Biology and Gene therapy directorate,
state officials from the department of health and delegates from the applicant’s side. Also in attendance
would be representatives from the Australian veterinary department whose purpose would be to verify
that indeed the proposed drug worked on dogs in the country.
Type of dossier to be submitted
This dossier will be characterized by the submission of a request to test the applicability of melanoma
antigen recognized by T-Cells (MART-1) gene from rats. This plasmid is proposed to be used to treat
malignant m...

flag Report DMCA

Good stuff. Would use again.

Similar Questions
Hot Questions
Related Tags
Study Guides

Brown University

1271 Tutors

California Institute of Technology

2131 Tutors

Carnegie Mellon University

982 Tutors

Columbia University

1256 Tutors

Dartmouth University

2113 Tutors

Emory University

2279 Tutors

Harvard University

599 Tutors

Massachusetts Institute of Technology

2319 Tutors

New York University

1645 Tutors

Notre Dam University

1911 Tutors

Oklahoma University

2122 Tutors

Pennsylvania State University

932 Tutors

Princeton University

1211 Tutors

Stanford University

983 Tutors

University of California

1282 Tutors

Oxford University

123 Tutors

Yale University

2325 Tutors